DOCS (Doximity) YoY EBITDA Growth: -41.73% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DOCS Doximity Inc DOCS
82 GF Score
Price $22.49
GF Value $49.30
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Doximity YoY EBITDA Growth?

Doximity DOCS +1.03% 82 YoY EBITDA Growth is -41.73% as of Mar. 2026. GuruFocus rates DOCS with a GF Score™ of 82/100 and a GF Value™ of $49.30 (Significantly Undervalued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Doximity's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -41.73%.

Doximity's EBITDA per Share for the three months ended in Mar. 2026 was $0.15.

Doximity YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Doximity's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Doximity YoY EBITDA Growth Chart

Doximity Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial 94.06 2.09 39.59 35.25 -3.76

Doximity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.93 16.80 15.52 -6.62 -41.73
DOCS
82GF Score
Doximity Inc DOCS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Doximity YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Doximity's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(1.152-1.197)/ | 1.197 |
=-3.76 %

Doximity's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(0.148-0.254)/ | 0.254 |
=-41.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -41.73% mean?
Doximity (DOCS) has a YoY EBITDA Growth of -41.73% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Doximity and its competitors.
Is Doximity's YoY EBITDA Growth too high?
Doximity's current YoY EBITDA Growth is -41.73%. Overall, Doximity has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's YoY EBITDA Growth compare to WAY and PRVA?
Doximity's YoY EBITDA Growth of -41.73% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Doximity and its competitors. Doximity's current YoY EBITDA Growth is -41.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (DOCS) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.30, compared to a current price of $22.49 — trading 54.4% below its estimated fair value. The current YoY EBITDA Growth is -41.73%. Doximity's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Doximity (DOCS), the current YoY EBITDA Growth is -41.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Doximity (DOCS) Overvalued in 2026?

Based on GuruFocus' analysis, Doximity stock appears to be undervalued. The current stock price of $22.49 is trading 54.4% below its estimated GF Value™ of $49.30. GuruFocus considers Doximity to be Significantly Undervalued.

Key valuation signals for DOCS:

  • YoY EBITDA Growth: -41.73%
  • GF Value™: $49.30 vs. price of $22.49 (54.4% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Doximity Business Description

Other Exchanges D2OC34:Brazil
Address 500 3rd Street, Suite 510, San Francisco, CA, USA, 94107
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
82GF Score

Get the complete analysis for DOCS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.49
Price
$49.30
GF Value